Last updated: February 13, 2026
Overview
NDC 50419-0454 is a prescription medication marketed in the United States. Its class, indications, competitive landscape, and current pricing provide insight into market dynamics and future pricing trends.
Product Description
- Manufacturer: Kyowa Kirin, Inc.
- Drug name: Erythropoietin-stimulating agent (ESA) used primarily for anemia in chronic kidney disease (CKD) and chemotherapy-induced anemia.
- Formulation: Subcutaneous or intravenous administration
- Approved indications include anemia associated with CKD, chemotherapy, and certain surgeries.
Market Size & Growth Drivers
The global ESA market was valued at approximately USD 4 billion in 2022, with U.S. sales representing ~60%. Growth factors include:
- Rising prevalence of CKD: An estimated 37 million adults in the U.S. suffer from CKD, with items expected to increase annually.
- Increasing cancer survivor base: Chemotherapy-induced anemia treatment drives demand.
- Treatment guidelines: Favor increased ESA use, but usage is moderated by safety concerns (e.g., thromboembolic events).
Competitive Landscape
Major competitors include:
| Drug Name |
Manufacturer |
Price Range (per dose) |
Approved Indications |
| Epogen (Epoetin alfa) |
Amgen |
USD 50–USD 70 |
CKD, chemotherapy, surgery |
| Procrit (Epoetin alfa) |
Johnson & Johnson |
Similar to Epogen |
Similar indications |
| Mircera (Methoxy polyethylene glycol-epoetin beta) |
Roche |
USD 70–USD 90 |
CKD, chemotherapy |
| NDC 50419-0454 |
Kyowa Kirin, Inc. |
USD 50–USD 80 per dose |
Primarily CKD, oncology support |
Prices vary based on dose, formulation, and payer negotiations. NDC 50419-0454's current retail prices approximate the lower end of the spectrum, competing directly with branded and biosimilar options.
Pricing Trends and Projections
-
Historical trends: Prices for ESAs have stabilized since 2017 after initial reductions prompted by biosimilar entry and policy changes.
-
Factors influencing future prices:
- Biosimilar competition due by 2024-2026 could pressure prices downward by 15-25%.
- Patent expiration for leading ESAs increases generic/biosimilar penetration.
- Policy shifts, such as Medicare reimbursement changes, can influence net prices.
-
Projected prices (2024–2028):
Prices are expected to decline modestly as biosimilars gain market share:
| Year |
Price per Dose |
Change from Prior Year |
Notes |
| 2024 |
USD 45–USD 75 |
0–10% decrease |
Market stabilization |
| 2025 |
USD 43–USD 70 |
2–8% decrease |
Continued biosimilar entry |
| 2026 |
USD 40–USD 65 |
2–7% decrease |
Biosimilar penetration |
| 2027–28 |
USD 38–USD 62 |
2–5% decrease |
Market consolidates |
Actual prices will depend substantially on payer negotiations and healthcare policies.
Regulatory & Reimbursement Environment
- FDA has approved biosimilars for epoetin alfa, increasing competitive pressure.
- CMS reimbursement policies favor biosimilar adoption, which could lead to further price reductions.
- Use restrictions and safety guidelines influence demand and pricing strategies.
Implications for Stakeholders
- Manufacturers should prepare for price erosion driven by biosimilar proliferation.
- Payers and providers benefit from increased biosimilar options, potentially reducing overall treatment costs.
- Investors should monitor biosimilar approvals, patent expirations, and policy changes as indicators of price trends.
Key Takeaways
- NDC 50419-0454 operates within a highly competitive ESA market.
- Prices are stable but likely to decline as biosimilars capture market share.
- The next 2–3 years will see moderate price decreases, influenced by biosimilar entry and policy shifts.
- Strategic market positioning requires anticipation of regulatory and reimbursement trends occurring in the near term.
FAQs
1. What factors most impact the pricing of NDC 50419-0454?
Biosimilar competition, patent expirations, healthcare policy changes, and payer negotiations.
2. How soon are biosimilars expected to affect the ESA market?
Biosimilar approvals for epoetin alfa are anticipated within the next 1–3 years; their market penetration will take additional time.
3. Will NDC 50419-0454 remain competitive?
Yes, but its market share may decrease as biosimilars lower industry prices, though branded formulations often retain premium positioning due to perceived safety and efficacy.
4. What are the key risks to price stability?
Regulatory changes, mandate shifts to biosimilars, and public safety concerns could accelerate price declines.
5. How does the U.S. market compare to global markets?
The U.S. has higher prices and more regulatory approval activity around biosimilars, leading to more rapid price declines compared to other regions.
Citations
[1] Market research data: IQVIA, 2022.
[2] FDA biosimilar approvals: FDA, 2023.
[3] Industry price analysis: Drugs.com, 2023.
[4] CMS reimbursement policies: CMS, 2023.
